Sound View Wealth Advisors Group LLC Has $1.43 Million Position in Pfizer Inc. $PFE

Sound View Wealth Advisors Group LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 37.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 57,441 shares of the biopharmaceutical company’s stock after selling 34,775 shares during the quarter. Sound View Wealth Advisors Group LLC’s holdings in Pfizer were worth $1,430,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Armstrong Advisory Group Inc. grew its position in shares of Pfizer by 46.5% in the 4th quarter. Armstrong Advisory Group Inc. now owns 10,484 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 3,328 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Pfizer by 3.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,414,548 shares of the biopharmaceutical company’s stock valued at $86,841,000 after acquiring an additional 105,368 shares during the last quarter. Gryphon Financial Partners LLC boosted its position in shares of Pfizer by 13.6% during the 4th quarter. Gryphon Financial Partners LLC now owns 9,305 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 1,117 shares in the last quarter. Wedmont Private Capital increased its holdings in Pfizer by 18.7% in the fourth quarter. Wedmont Private Capital now owns 36,991 shares of the biopharmaceutical company’s stock worth $935,000 after purchasing an additional 5,825 shares in the last quarter. Finally, Value Partners Investments Inc. increased its stake in shares of Pfizer by 0.4% in the 4th quarter. Value Partners Investments Inc. now owns 164,624 shares of the biopharmaceutical company’s stock valued at $4,100,000 after acquiring an additional 624 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.14.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Trading Down 1.6%

Pfizer stock opened at $26.98 on Friday. The firm’s fifty day moving average price is $26.68 and its 200-day moving average price is $25.61. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The stock has a market cap of $153.41 billion, a P/E ratio of 19.84 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.63 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.